SG11201408651TA - Use of markers in the diagnosis and treatment of prostate cancer - Google Patents

Use of markers in the diagnosis and treatment of prostate cancer

Info

Publication number
SG11201408651TA
SG11201408651TA SG11201408651TA SG11201408651TA SG11201408651TA SG 11201408651T A SG11201408651T A SG 11201408651TA SG 11201408651T A SG11201408651T A SG 11201408651TA SG 11201408651T A SG11201408651T A SG 11201408651TA SG 11201408651T A SG11201408651T A SG 11201408651TA
Authority
SG
Singapore
Prior art keywords
keratin
international
iii
llll
prostate cancer
Prior art date
Application number
SG11201408651TA
Inventor
Niven Rajin Narain
Rangaprasad Sarangarajan
Vivek K Vishnudas
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of SG11201408651TA publication Critical patent/SG11201408651TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4742Keratin; Cytokeratin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/004931 A1 (51) International Patent Classification: C12Q 1/68 (2006.01) G01N33/68 (2006.01) G01N 33/574 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 61/665,201 61/672,090 61/673,094 61/702,523 61/718,080 61/718,081 61/718,064 27 June 2012 (27.06.2012) 16 July 2012 (16.07.2012) 18 July 2012 (18.07.2012) 18 September 2012 (18.09.2012) 24 October 2012 (24.10.2012) 24 October 2012 (24.10.2012) 24 October 2012 (24.10.2012) PCT/US2013/048373 27 June 2013 (27.06.2013) English English US US us us us us us (71) Applicant: BERG PHARMA LLC [US/US]; 1845 Elm Hill Pike, Nashville, TN 37210 (US). (72) Inventors: NARAIN, Niven Rajin; 73 Fresh Pond Park­ way, Cambridge, MA 02138 (US). SARANGARAJAN, Rangaprasad; 454 Central Street, Boylston, MA 01505 (US). VISHNUDAS, Vivek K.; 91 Stamford Street, Apt. #1, Newton, MA 02466 (US). (74) Agents: HANLEY, Elizabeth A. et al.; McCarter & Eng­ lish, LLP, 265 Franklin Street, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [Continued on next page] (54) Title: USE OF MARKERS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER FIG. 7 10000 \"• .g 1000 c o o OJ •I OJ >- 0\ •t o o 100 10 Mean LY9 Levels in Human Serum n=2 p=0.225 • J A A • • • ~T W~ vT ' • ' ^• T (57) Abstract: The invention provides method for diagnosis, monitoring, and pro­ gnosis of prostate cancer using one or more of keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9, and PSA. The inven­ tion provides kits for practicing the meth­ ods of the invention. Prostate Cancer Normal Donors o CJ o & wo 2014/004931 AI III llll IIII III III Hill III III III Hill Hill lllll II llll 111 lllllll llll 111 llll TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) — with international search report (Art. 21(3))
SG11201408651TA 2012-06-27 2013-06-27 Use of markers in the diagnosis and treatment of prostate cancer SG11201408651TA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261665201P 2012-06-27 2012-06-27
US201261672090P 2012-07-16 2012-07-16
US201261673094P 2012-07-18 2012-07-18
US201261702523P 2012-09-18 2012-09-18
US201261718081P 2012-10-24 2012-10-24
US201261718080P 2012-10-24 2012-10-24
US201261718064P 2012-10-24 2012-10-24
PCT/US2013/048373 WO2014004931A1 (en) 2012-06-27 2013-06-27 Use of markers in the diagnosis and treatment of prostate cancer

Publications (1)

Publication Number Publication Date
SG11201408651TA true SG11201408651TA (en) 2015-01-29

Family

ID=49783880

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408651TA SG11201408651TA (en) 2012-06-27 2013-06-27 Use of markers in the diagnosis and treatment of prostate cancer

Country Status (16)

Country Link
US (3) US20140038838A1 (en)
EP (1) EP2867375B1 (en)
JP (2) JP6352909B2 (en)
KR (1) KR20150023904A (en)
CN (1) CN104583422A (en)
AU (1) AU2013284448B2 (en)
BR (1) BR112014032728A2 (en)
CA (1) CA2877721A1 (en)
EA (1) EA201492284A1 (en)
ES (1) ES2720763T3 (en)
HK (1) HK1209792A1 (en)
IL (1) IL236482A0 (en)
MX (1) MX360236B (en)
NZ (1) NZ703411A (en)
SG (1) SG11201408651TA (en)
WO (1) WO2014004931A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3102600T3 (en) * 2014-02-05 2019-04-01 Fujirebio Diagnostics Ab COMPOSITION AND PROCEDURE FOR DETECTIVE DEPARTURAL NEOPLASTIC DISEASE
SG10201808585TA (en) 2014-03-28 2018-11-29 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
KR102657306B1 (en) 2014-12-08 2024-04-12 버그 엘엘씨 Use of markers including filamin a in the diagnosis and treatment of prostate cancer
ES2867798T3 (en) 2015-03-27 2021-10-20 Opko Diagnostics Llc Prostate Antigen Standards and Uses of These
KR20190034503A (en) * 2016-06-03 2019-04-02 이투빅스 코포레이션 Composition and method for tumor vaccination using prostate cancer-associated antigen
US20180024132A1 (en) * 2016-07-07 2018-01-25 Berg Llc Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
WO2018189292A1 (en) * 2017-04-13 2018-10-18 Institut National De La Sante Et De La Recherche Medicale Biomarkers of castration-resistant prostatic cells
KR102405789B1 (en) * 2018-08-24 2022-06-07 고려대학교 세종산학협력단 A biomaker composition for diagnosing prostate cancer comprising a kynurenine pathway metabolome
CN109608536B (en) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 Epitope polypeptide CD44-P3 based on prostate cancer stem cell marker CD44 and application thereof
CN109608537B (en) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 Epitope polypeptide CD44-P2 based on prostate cancer stem cell marker CD44 and application thereof
KR102497196B1 (en) * 2020-09-08 2023-02-07 (주)유로테크 A method to calculate a diagnostic score for a prostate cancer and use thereof
CN114134223B (en) * 2021-12-02 2022-10-11 青岛市中心血站 Blood detection kit for hepatitis C virus-related liver fibrosis

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942999C2 (en) 1989-12-27 1997-12-18 Progen Biotechnik Gmbh Procedure for the detection of malignant diseases
DE4208422A1 (en) 1992-03-16 1993-09-30 Boehringer Mannheim Gmbh Method for the detection of micrometastases of ectodermal or endodermal tumors
WO1997035589A1 (en) 1996-03-26 1997-10-02 Kopreski Michael S Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US6107103A (en) * 1996-10-15 2000-08-22 Procyon Bropharma Inc. Assay for PSP94 protein
WO1999014372A1 (en) 1997-09-15 1999-03-25 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
ATE249236T1 (en) 1998-10-22 2003-09-15 Curagen Corp PREDICTIVE AND THERAPEUTIC FOR KIDNEY DISEASE GENES AND PROTEINS
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
CA2404431C (en) 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
JP2004512029A (en) 2000-08-16 2004-04-22 カイロン コーポレイション Human genes and gene expression products
US20030073144A1 (en) 2001-01-30 2003-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
EP1364069B1 (en) 2001-03-01 2009-04-22 Epigenomics AG Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
EP2799555B1 (en) 2002-03-13 2017-02-22 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
WO2003097878A1 (en) 2002-05-21 2003-11-27 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
EP1585482A4 (en) 2002-09-25 2009-09-09 Genentech Inc Nouvelles compositions et methodes de traitement du psoriasis
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US20040109863A1 (en) * 2002-12-04 2004-06-10 Peter Emtage Methods of therapy and diagnosis using targeting of cells that express Ly-9
DE10259703A1 (en) 2002-12-19 2004-07-08 Ivonex Gmbh separation process
JP5479663B2 (en) 2002-12-20 2014-04-23 セレラ コーポレーション Genetic polymorphism associated with myocardial infarction, detection method and use thereof
WO2004076614A2 (en) * 2003-02-27 2004-09-10 Bernd Hinzmann Human nucleic acid sequences obtained from prostatic carcinomas
CA2519630A1 (en) 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
JP2007507222A (en) 2003-05-28 2007-03-29 ゲノミック ヘルス, インコーポレイテッド Gene expression markers for predicting response to chemotherapy
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
EP1892306A3 (en) 2003-10-06 2008-06-11 Bayer HealthCare AG Methods and kits for investigating cancer
ITPD20030264A1 (en) 2003-10-30 2005-04-30 Xeptagen Spa HIGHLY SPECIFIC DIAGNOSIS METHOD FOR NEOPLASIA
CN1743849A (en) 2004-09-03 2006-03-08 上海透景生命科技有限公司 Multi tumour tag parallel detecting method and kit
US20060057127A1 (en) 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
US20060063214A1 (en) 2004-09-17 2006-03-23 Ozge Alper Methods and compositions for diagnosing neoplastic disease
EP1815021A2 (en) 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
DE602006016085D1 (en) 2005-03-16 2010-09-23 Genentech Inc BIOLOGICAL MARKERS PREDICTIVE FOR THE APPLICATION OF CANCER TO INHIBITORS OF THE CINEMA OF THE RECEPTOR FOR EPIDERMAL GROWTH FACTOR
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US9234897B2 (en) 2005-03-31 2016-01-12 Two Cells Co., Ltd Method for distinguishing mesenchymal stem cell using molecular marker and use thereof
EP1910564A1 (en) 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
EP1883705A4 (en) 2005-05-25 2009-02-25 Expression Pathology Inc Multiplex method for increased proteomic coverage from histopathologically processed biological samples using liquid tissue preparations
EP1907845A4 (en) * 2005-05-25 2009-03-04 Expression Pathology Inc Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan Compositions and methods for treating and diagnosing cancer
EP1734118A1 (en) 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening
US7842466B1 (en) 2005-09-16 2010-11-30 Celera Corporation Colon disease targets and uses thereof
AU2006304605A1 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
WO2007119111A2 (en) 2005-11-10 2007-10-25 Aurelium Biopharma Inc. Tissue diagnostics for ovarian cancer
WO2007071947A1 (en) * 2005-12-19 2007-06-28 University Of Hull Cancer screening test
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
JP4968577B2 (en) 2006-04-11 2012-07-04 エフ.ホフマン−ラ ロシュ アーゲー Rapid measurement method of cytokeratin 19 (CK19) mRNA, and primer and probe therefor
US20080003624A1 (en) 2006-06-13 2008-01-03 Sysmex Corporation Cancer metastasis determination method
US7901902B2 (en) 2006-07-27 2011-03-08 Biosante Pharmaceuticals, Inc. Methods and compositions for identifying a cellular immune response against prostate cancer
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
US8642349B1 (en) 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US8748108B2 (en) 2006-09-05 2014-06-10 Abbvie Inc. Biomarkers for identifying patient classes
ES2375453T3 (en) 2006-09-07 2012-03-01 Universitätsklinikum Hamburg-Eppendorf METHOD FOR THE DETECTION OF CANCER EPITHELIAL CELLS USING CYTOKERATINS RELEASED AS MARKERS FOR SUCH CELLS.
RU2473555C2 (en) 2006-12-19 2013-01-27 ДжинГоу, Инк. New method for functional analysis of body of experimental data and gene groups identified from said data
CA2679664C (en) * 2007-03-02 2017-04-25 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2008121307A2 (en) * 2007-03-28 2008-10-09 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
WO2008144345A2 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US20090221004A1 (en) 2007-06-01 2009-09-03 Anita Lim Hong Caspase-cleavage anti-keratin antibodies for detection of apoptosis
EP2201134B1 (en) 2007-09-19 2018-11-21 The Research Foundation of State University of New York Gene expression signatures in enriched tumor cell samples
AU2008307579A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
MX2010004671A (en) 2007-12-10 2010-05-27 Hoffmann La Roche Seprase as a marker for cancer.
SG10201609507TA (en) 2008-02-01 2017-01-27 Gen Hospital Corp Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US8008032B2 (en) 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
US20110265197A1 (en) 2008-07-16 2011-10-27 Dana-Farber Cancer Institute, Inc. Signatures and PCDeterminants Associated with Prostate Cancer and Methods of Use Thereof
US9127078B2 (en) 2008-07-21 2015-09-08 The Trustees Of The University Of Pennsylvania Methods and compositions using splicing regulatory proteins involved in tumor suppression
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
IT1391619B1 (en) 2008-11-04 2012-01-11 Silicon Biosystems Spa METHOD FOR THE IDENTIFICATION, SELECTION AND ANALYSIS OF TUMOR CELLS
CA2742286C (en) 2008-11-12 2016-08-09 F. Hoffmann-La Roche Ag Pacap as a marker for cancer
CN102308212A (en) 2008-12-04 2012-01-04 加利福尼亚大学董事会 Materials and methods for determining diagnosis and prognosis of prostate cancer
ES2490613T3 (en) 2008-12-22 2014-09-04 F. Hoffmann-La Roche Ag ARMET as a cancer marker
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
JP2012100536A (en) 2009-03-02 2012-05-31 Genescience Co Ltd Genetic testing method for cancer by analysis of expression of cancer-relating gene utilizing monocyte contained in blood sample
WO2010099918A1 (en) 2009-03-06 2010-09-10 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
US10815517B2 (en) 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
WO2011040532A1 (en) * 2009-10-02 2011-04-07 学校法人 久留米大学 Method for predicting therapeutic effect of immunotherapy on cancer patient and/or prognosis after immunotherapy, and gene set and kit to be used therein
WO2011053837A1 (en) 2009-10-29 2011-05-05 King Kutter, Inc. Stump cutter
EP2335838B1 (en) 2009-12-18 2012-09-26 Deutsche Post AG Sorting system and method using a portable device
US20130095503A1 (en) 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
US20110177525A1 (en) 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
US8664472B2 (en) 2010-04-28 2014-03-04 Sesaco Corporation Pygmy sesame plants for mechanical harvesting
EP2390665A1 (en) * 2010-05-27 2011-11-30 Atlas Antibodies AB Prostate cancer biomarkers
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
US8557777B2 (en) 2010-07-09 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
CA2807811A1 (en) * 2010-07-28 2012-02-02 Metabolon Inc. Biomarkers for prostate cancer and methods using the same
US9040464B2 (en) 2010-08-16 2015-05-26 Mount Sinai Hosptial Markers of the male urogenital tract
WO2012024543A1 (en) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
US9255142B2 (en) 2010-09-09 2016-02-09 Beijing Cotimes Biotech Co., Ltd. Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
US9347953B2 (en) 2010-12-06 2016-05-24 Thd S.P.A. Method for the diagnosis of a carcinoma and uses thereof
WO2012083338A1 (en) 2010-12-24 2012-06-28 Map Diagnostics Pty Ltd. Selective reaction monitoring (srm) derived protein profiles for cancer and other pathologic entities
WO2012101283A1 (en) 2011-01-28 2012-08-02 Biosystems International Sas Combinatorial biomarkers for clinical applications in lung cancer patient management
US9926601B2 (en) 2011-02-24 2018-03-27 Massachusetts Institute Of Technology Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer
KR101320633B1 (en) 2011-05-25 2013-10-30 엠앤디 (주) Method of providing information for diagnosis of cancer using quantitative realtime PCR and diagnostic kit comprising thereof
WO2012135397A2 (en) 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
EP2551673B1 (en) 2011-07-26 2016-01-20 Universidad de Salamanca Methods for the detection of cancer infiltration of the central nervous system
CA2844671A1 (en) 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
CN106526186A (en) 2011-09-12 2017-03-22 克里蒂科斯有限责任公司 Non-invasive method for detecting target molecules
WO2013134786A2 (en) 2012-03-09 2013-09-12 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
WO2013148316A1 (en) 2012-03-29 2013-10-03 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
TWI468519B (en) 2012-09-05 2015-01-11 Univ China Medical Methods of detecting squamous cell carcinoma in vitro
US20150226744A1 (en) 2012-09-17 2015-08-13 Ait Austrian Institute Of Technology Gmbh Colon Cancer Diagnostic Method and Means
US9201061B2 (en) 2013-02-26 2015-12-01 Industry-University Cooperation Foundation Hanyang University KRT19 stabilizing HER2 and use thereof
CA2902841A1 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
SE538211C2 (en) 2013-04-05 2016-04-05 Idl Biotech Ab Method for detecting cytokeratin 8, 18 and / or 19 and / or soluble fragments thereof
US20150079590A1 (en) 2013-09-18 2015-03-19 Beth Israel Deaconess Medical Center, Inc. Characterization and analysis of the composition and dynamics of the mammalian riboproteome
EP3693738A1 (en) 2013-09-20 2020-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain

Also Published As

Publication number Publication date
JP2015523569A (en) 2015-08-13
US20160178632A1 (en) 2016-06-23
JP6581247B2 (en) 2019-09-25
CA2877721A1 (en) 2014-01-03
EP2867375B1 (en) 2019-02-27
AU2013284448B2 (en) 2019-04-18
KR20150023904A (en) 2015-03-05
MX2015000008A (en) 2015-04-10
JP6352909B2 (en) 2018-07-04
US20180031563A1 (en) 2018-02-01
EP2867375A4 (en) 2016-06-01
BR112014032728A2 (en) 2017-11-28
WO2014004931A1 (en) 2014-01-03
AU2013284448A1 (en) 2015-01-22
JP2018163164A (en) 2018-10-18
IL236482A0 (en) 2015-02-26
HK1209792A1 (en) 2016-04-08
MX360236B (en) 2018-10-26
CN104583422A (en) 2015-04-29
EA201492284A1 (en) 2015-11-30
ES2720763T3 (en) 2019-07-24
EP2867375A1 (en) 2015-05-06
US9797905B2 (en) 2017-10-24
NZ703411A (en) 2017-09-29
US20140038838A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
SG11201408651TA (en) Use of markers in the diagnosis and treatment of prostate cancer
SG11201407569PA (en) Interrogatory cell-based assays for identifying drug-induced toxicity markers
SG11201407370QA (en) Humanized il-7 rodents
SG11201908391XA (en) Methods for modulating an immune response
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201805380YA (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy
SG11201408261UA (en) Syringe
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201408228QA (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201406943XA (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201407890VA (en) Tetrahydropyrazolopyrimidine compounds
SG11201806861SA (en) Combination therapy with anti-cd73 antibodies
SG11201808812RA (en) Novel aav8 mutant capsids and compositions containing same
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201810287RA (en) Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
SG11201407561UA (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201407880QA (en) Treatment of solid tumors using coenzyme q10